Roche says EU regulator panel backs Susvimo approval for wet AMD

Reuters2026/07/24 10:15

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

EU drug regulator CHMP recommended approval of Roche’s Susvimo for neovascular age-related macular degeneration, paving the way for a European Commission decision.
Susvimo uses the Contivue refillable eye implant to continuously deliver ranibizumab, positioned as an alternative to frequent anti-VEGF injections.
Archway, LADDER, Portal data showed vision outcomes comparable to monthly ranibizumab injections; about 95% needed no supplemental anti-VEGF with two refills yearly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240615OMX_____CNEWS_EN_GNW1001214281_en) on July 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Roche says EU regulator panel backs Susvimo approval for wet AMD

You may also like

Crypto prices